Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease

Launched by COPKA SONPASHAN · Mar 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a procedure called Stellate Ganglion Block on patients with Cerebral Small Vessel Disease, which can cause problems with swallowing (dysphagia) and thinking (cognitive impairment). The trial will compare two groups of patients: one group will receive the Stellate Ganglion Block in addition to regular therapy, while the other group will only receive routine therapy. Researchers will evaluate how well patients can swallow, think, and perform daily activities before and after the treatment.

To be eligible for this trial, participants must be over 18 years old and diagnosed with Cerebral Small Vessel Disease. They should also have trouble swallowing confirmed by a specific swallowing test and show signs of cognitive impairment. However, those with swallowing or cognitive issues caused by other medical conditions, or who have had a stroke, will not be included. The trial is not yet recruiting participants, but if selected, individuals can expect thorough assessments of their swallowing and thinking abilities throughout the study to see how effective the Stellate Ganglion Block might be in improving their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age\>18 years.
• • Meeting the diagnostic criteria for cerebral small vessel disease.
• • Dysphagia confirmed by Videofluoroscopic Swallowing Study
• • Mini-Mental State Examination (MMSE)\<27, indicating the existence of cognitive impairment.
• • No history of prior stroke.
• • Stable vital signs.
• Exclusion Criteria:
• • Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc.
• • Cognitive impairment that might be caused by other diseases, such as Alzheimer's disease.
• • Neurological blockade contraindications such as bleeding tendency, blocked site infection.
• • Unable to successfully finish the assessment of this study.
• • Complicated with severe liver and kidney failure, tumors, or hematological disorders.
• • Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
• • Pregnant or nursing females